Inflammation & CVD: Translating insights from vascular biology to the clinicNov. 16, 2017 - Prof. Peter Libby, USA
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab
Video navigation menu
- IL-1β as a target for atherosclerosis therapy 00:33
- IL-1 induces the production of IL-6, a key mediator of the acute phase response 02:56
- IL-1β is activated by caspase 1, which is overexpressed in human atherosclerotic plaques 05:23
- Clonal hematopoiesis and risk of atherosclerotic CVD 07:29
- CANTOS trial: design & outcomes 08:41
- Effects of IL-1 blockade on cellular functions 10:17
This educational video is part of a series of Inflammation videos that are aimed to provide guidance and perspectives on the implications of addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Prof. Peter Libby is Mallinckrodt Professor of Medicine, Harvard Medical School; Senior Physician, Brigham and Women's Hospital, Boston, MA, USA
Funding to produce this educational video was provided by an unrestricted educational grant from Novartis.